3.4.10 Antigen-specific cellular therapy

CellExSys is developing a product that is called "patient-specific." It uses the patient’s own T-cells, and exposes them to HCV, causing them to create antibodies against the virus. These antigen-specific T-cells are then cloned to make a multitude of cells which are reinjected into the patient. The treatment has been proven effective in animal studies, and human studies in Hep C patients are planned in 2003.